Literature DB >> 10542391

Delivery of peptide and non-peptide drugs through the respiratory tract.

.   

Abstract

The respiratory tract, and the nose in particular, offers opportunities for improved drug delivery. Many drugs are rapidly and efficiently absorbed from the nasal cavity and, as a result, the nasal route may be used in crisis treatments (for example, for pain and nausea). Polar drugs, such as peptides and proteins, are not well absorbed across the nasal mucosa, unless they are delivered with an absorption enhancing material. Agents, such as the polysaccharide chitosan, that are able to open tight junctions between cells can offer important opportunities. The nasal route can also be used for the delivery of vaccines. This review makes a comparison between nasal and pulmonary delivery.

Entities:  

Year:  1999        PMID: 10542391     DOI: 10.1016/s1461-5347(99)00199-6

Source DB:  PubMed          Journal:  Pharm Sci Technolo Today        ISSN: 1461-5347


  10 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 3.  An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension.

Authors:  Vinit Agnihotri; Yogeeta Agrawal; Sameer Goyal; Charu Sharma; Shreesh Ojha
Journal:  Molecules       Date:  2022-05-29       Impact factor: 4.927

4.  A Therapeutically Active Minibody Exhibits an Antiviral Activity in Oseltamivir-Resistant Influenza-Infected Mice via Direct Hydrolysis of Viral RNAs.

Authors:  Yongjun Lee; Phuong Thi Hoang; Dongjun Kim; Ramadhani Qurrota Ayun; Quynh Xuan Thi Luong; Kyungho Na; Taehyun Kim; Yeonsu Oh; Won-Keun Kim; Sukchan Lee
Journal:  Viruses       Date:  2022-05-21       Impact factor: 5.818

5.  Preparation and characterization of theophylline loaded chitosan/beta-cyclodextrin microspheres.

Authors:  Wei Fen Zhang; Xi Guang Chen; Pi Wu Li; Qiang Zhi He; Hui Yun Zhou
Journal:  J Mater Sci Mater Med       Date:  2007-06-28       Impact factor: 3.896

6.  Biocompatibility study of theophylline/chitosan/beta-cyclodextrin microspheres as pulmonary delivery carriers.

Authors:  Wei Fen Zhang; Hui Yun Zhou; Xi Guang Chen; Shu Hong Tang; Jing Jing Zhang
Journal:  J Mater Sci Mater Med       Date:  2009-01-10       Impact factor: 3.896

7.  Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants.

Authors:  Libo Wu; Balaji Bharatwaj; Jayanth Panyam; Sandro R P da Rocha
Journal:  Pharm Res       Date:  2007-10-17       Impact factor: 4.200

8.  Chitosan-modified dry powder formulations for pulmonary gene delivery.

Authors:  Hao-Ying Li; James Birchall
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.580

Review 9.  New treatments for viral respiratory tract infections--opportunities and problems.

Authors:  N J Snell
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

10.  Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries.

Authors:  Richard J Prankerd; Tri-Hung Nguyen; Jibriil P Ibrahim; Robert J Bischof; Gemma C Nassta; Livesey D Olerile; Adrian S Russell; Felix Meiser; Helena C Parkington; Harold A Coleman; David A V Morton; Michelle P McIntosh
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.